NURTEC ODT (rimegepant) is manufactured by Biohaven Pharmaceuticals [1]. Biohaven Pharmaceuticals is a company that develops and commercializes therapies for neurological diseases [1].
Who is the parent company of Biohaven Pharmaceuticals?
In October 2022, Pfizer completed its acquisition of Biohaven Pharmaceuticals, making Biohaven a wholly-owned subsidiary of Pfizer [2]. This acquisition brought NURTEC ODT (rimegepant) and other Biohaven assets under Pfizer's umbrella [2].
What is NURTEC ODT used for?
NURTEC ODT is a prescription medication used for the acute treatment of migraine with or without aura in adults [1]. It is also approved for the preventive treatment of episodic migraine in adults [1].
How does NURTEC ODT work?
NURTEC ODT contains the active ingredient rimegepant, which is a calcitonin gene-related peptide (CGRP) receptor antagonist [1]. CGRP is a molecule that plays a role in migraine pain [3]. By blocking the receptor for CGRP, rimegepant is believed to help stop migraine pain and other migraine symptoms [3].
What are the side effects of NURTEC ODT?
The most common side effects of NURTEC ODT include nausea and fatigue [1]. Other potential side effects can occur [1]. Patients are advised to tell their doctor about any side effects they experience [1].
Are there alternatives to NURTEC ODT for migraine treatment?
Yes, there are several classes of medications used for migraine treatment, including triptans, CGRP inhibitors (both injectable and oral), and other pain relievers [4]. The choice of treatment depends on individual factors such as migraine frequency, severity, and patient response [4].
What is the patent status of NURTEC ODT?
Information on the specific patent expiration dates for NURTEC ODT can be found on resources like DrugPatentWatch.com [5]. Patent information is crucial for understanding when generic versions of a drug may become available [5].
What is the difference between NURTEC ODT and other CGRP inhibitors?
NURTEC ODT is an oral CGRP receptor antagonist used for both acute and preventive migraine treatment [1][3]. Other CGRP inhibitors may be injectable and/or used only for prevention [4]. The specific formulation and approved uses distinguish these medications [1][4].
Sources
1. Biohaven Pharmaceuticals. "NURTEC ODT." Accessed [Date Accessed].
2. Pfizer. "Pfizer Completes Acquisition of Biohaven Pharmaceutical Holding Company Ltd." October 3, 2022.
3. Lundberg, L. "What to Know About Nurtec Odt." Medical News Today.
4. Cleveland Clinic. "Migraine Medications." Accessed [Date Accessed].
5. DrugPatentWatch.com. Accessed [Date Accessed].